Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis

ABSTRACT: Objective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China. Materials and methods: A Markov model was developed to estimate the long-term health and economic outcomes of radium-223 plus best standard care (BSC) treatment and BSC only for bone mCRPC patients over a lifetime horizon. The patients and interventions were modeled according to the ALSYMPCA trial. Costs were collected from a Chinese health system perspective. Utility values were derived from the published literature. The base-case model results were quality-adjusted life year (QALY), total cost, and incremental cost-utility ratio (ICUR). Uncertainty analyses were performed to assess the robustness of our conclusions. Results: Compared wit

SUBMITTER: Zeng X 

PROVIDER: S-EPMC9633991 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature